Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of DWP14012 (Fexuprazan) in Healthy Male Volunteers
NCT02757144Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Mar 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fexuprazan in gastroesophageal reflux disease (GERD) (6 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Number and percentage of Participants With Adverse Events (AE), Number and percentage of Participants With Adverse Drug Reactions (ADR) and 3 more. Started Mar 2016; status: completed.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02757144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02757144.